# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Diagnostics Advisory Committee (DAC) meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 18 April 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Brian Shine (Chair) Present for all items
2. Keith Abrams Present for all items
3. Ghada Ahmed Present for all items
4. Rebecca Allcock Present for all items
5. John Cairns Present for all items
6. Diane Davies Present for all items
7. Neil Hawkins Present for all items
8. Rashmi Kumar Present for all items
9. Patrick McGinley Present for all items
10. Radha Ramachandran Present for all items
11. Matt Stevenson Present for all items
12. Jonathan Weir-McCall Present for all items

NICE staff present

Rebecca Albrow, Associate Director, Diagnostics Assessment Present for all items

Programme (DAP)

Thomas Walker, Health Technology Assessment Adviser, DAP Present for all items

Jacob Grant, Health Technology Assessment Analyst, DAP Present for all items

Emma McCarthy, Associate Health Technology Assessment Present for all items   
Analyst

Toni Gasse, Project Manager, DAP Present for all items

Harriet Wilson, Project Manager, DAP Present for all items

Lyn Davies, Meetings in Public Present for items 1 to 1.1.5

External assessment group representatives present

Joe Carroll, Senior Research Associate, Bristol Technology Present for items 1 to 1.1.5   
Assessment Group

Penny Whiting, Professor of Clinical Epidemiology, Present for items 1 to 1.1.5

Bristol Technology Assessment Group

**Specialist Committee Members present**

Mark Cadman, Lay specialist committee member Present for all items

Alexander Doney, Senior Clinical Lecturer and Present for all items  
Honorary Consultant Physician

Salim Elyas, Consultant Stroke Physician Present for all items

Albert Ferro, Professor of Cardiovascular Clinical Present for all items  
Pharmacology

Dheeraj Kalladka, Consultant Neurologist & Stroke Physician Present for all items

Dagan Lonsdale, Senior Lecturer in Clinical Present for all items  
Pharmacology and Honorary Consultant Intensivist

Paresh Parmar, Lead Pharmacist Stroke and Older People Present for all items

Michelle Wood, Principal Clinical Scientist Present for all items

Observers present

Jean Isaac, Health Technology Assessment Analyst Present for all items

Anam Khan, Health Technology Assessment Analyst Present for all items

Rebecca Boucher, Senior Medical Editor Present for all items

Matthew Brown, Digital Media Manager Present for all items

Benjamin Pearce, Senior Medical Editor Present for all items

## Suzie Panek, Resource Impact Assessment Present for all items

## Minutes

### Assessment of ‘Clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack’

### The Chair welcomed members of the committee and other attendees present to the meeting.

The Chair noted apologies from standing committee members Joy Allen, Sam Creavin, Brendan Meyer, Michael Messenger, Anne Scott, and Karen Sennett and from specialist committee member Daniel Burrage.

* 1. Part 1 – Open session

The Chair welcomed external assessment group representatives, members of the public, and company representatives from Genedrive Diagnostics Ltd and Genomadix.

* + 1. The Chair asked all committee and specialist committee members to declare any new relevant interests in relation to the topic being considered in addition to those declared in advance of the meeting. Declaration of interest for this assessment can be found on the assessment web page: <https://www.nice.org.uk/guidance/indevelopment/gid-dg10054>
    2. The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of ‘Clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack’. The Committee was asked if there were any specific equality issues to consider in relation to this assessment.
    3. The Chair asked the representatives of the companies whether they wished to comment on any matters of factual accuracy.
    4. The Chair thanked the company representatives, the EAG and public observers for their attendance at the meeting.
    5. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and company representatives, EAG representatives and members of the public left the meeting.
  1. Part 2 - Closed session
     1. The committee discussed confidential information submitted for this item.
     2. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached by consensus.
     3. The committee asked the NICE technical team to prepare the Draft Guidance (DG) in line with their decisions.

### Date of the next meeting

The next meeting of the Diagnostics Advisory Committee (next topic) will be held on 24 May 2023.